Zoetis Inc. (NYSE:ZTS) Receives $120.83 Consensus Target Price from Brokerages

Shares of Zoetis Inc. (NYSE:ZTS) have been assigned a consensus rating of “Hold” from the seventeen analysts that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $120.8333.

Several equities analysts have weighed in on the company. JPMorgan Chase & Co. reduced their price objective on Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Citigroup cut their price target on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a report on Monday, May 18th. Stifel Nicolaus cut their price objective on Zoetis from $95.00 to $85.00 and set a “hold” rating for the company in a report on Friday, June 26th. Weiss Ratings lowered Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 12th. Finally, UBS Group cut their price objective on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research note on Friday, May 8th.

Insider Buying and Selling at Zoetis

In other Zoetis news, Director Frank A. Damelio purchased 6,650 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The stock was bought at an average price of $75.39 per share, with a total value of $501,343.50. Following the completion of the purchase, the director directly owned 21,458 shares of the company’s stock, valued at $1,617,718.62. The trade was a 44.91% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Paul Bisaro bought 2,000 shares of the business’s stock in a transaction dated Wednesday, May 13th. The shares were bought at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the purchase, the director directly owned 27,862 shares in the company, valued at approximately $2,114,168.56. This represents a 7.73% increase in their position. The SEC filing for this purchase provides additional information. Over the last quarter, insiders have bought 11,650 shares of company stock worth $886,384. 0.22% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Zoetis

Institutional investors have recently added to or reduced their stakes in the company. Tema ETFs LLC boosted its position in shares of Zoetis by 18.9% in the 2nd quarter. Tema ETFs LLC now owns 8,984 shares of the company’s stock worth $646,000 after purchasing an additional 1,431 shares in the last quarter. Handelsbanken Fonder AB raised its stake in Zoetis by 10.7% during the second quarter. Handelsbanken Fonder AB now owns 228,467 shares of the company’s stock valued at $16,418,000 after buying an additional 21,990 shares during the last quarter. Fulton Bank N.A. boosted its holdings in Zoetis by 6.1% in the second quarter. Fulton Bank N.A. now owns 11,366 shares of the company’s stock worth $817,000 after acquiring an additional 652 shares in the last quarter. Wealthcare Capital Partners LLC grew its stake in shares of Zoetis by 97.4% in the second quarter. Wealthcare Capital Partners LLC now owns 4,195 shares of the company’s stock worth $301,000 after acquiring an additional 2,070 shares during the last quarter. Finally, Deane Retirement Strategies Inc. bought a new position in shares of Zoetis during the second quarter valued at $2,247,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

ZTS opened at $76.17 on Friday. The firm’s fifty day moving average price is $77.32 and its two-hundred day moving average price is $105.54. The company has a market capitalization of $31.93 billion, a price-to-earnings ratio of 12.63, a P/E/G ratio of 1.19 and a beta of 0.75. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. Zoetis has a 1 year low of $71.47 and a 1 year high of $160.48.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The firm had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The firm’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same period in the previous year, the business earned $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, analysts anticipate that Zoetis will post 6.87 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a $0.53 dividend. The ex-dividend date is Monday, July 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.8%. Zoetis’s dividend payout ratio (DPR) is currently 35.16%.

Key Stories Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis saw unusual options activity, with traders buying 8,095 call options, about 59% above the average daily volume, suggesting some speculative bullish interest.
• Neutral Sentiment: Several law firms, including Rosen Law Firm, Glancy Prongay Wolke & Rotter LLP, the Schall Law Firm, Bronstein Gewirtz & Grossman LLC, DJS Law Group, and Bragar Eagel & Squire, reminded investors about a July 27 lead-plaintiff deadline in an existing class action related to Zoetis securities purchased between January 14, 2025 and May 6, 2026. Article Title
• Negative Sentiment: The class-action campaign keeps attention on alleged securities-law violations, which can create legal uncertainty and pressure the stock until the case is resolved. Article Title

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.